NP30179
A clinical trial to safety and effectiveness of new treatment NP30179 given alone or in combination with Obinituzumab in patients with B-cell non-Hodgkin’s lymphomas.
Cancer type
B-cell non-Hodgkin’s lymphomas – follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL) including patients who show Richter’s transformation.
Status
Open and recruiting
Phase
One: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one is to test the safety of the new treatment and find the best dose to give patients.
Brief summary
The purpose of this clinical trial is to find the best dose of a new treatment RO7082859, given alone or in combination with Obinituzumab and how effective it is on certain cancers. The treatment RO7082859 is a T-cell bispecific antibody which works by activating or supporting the body’s own immune system to identify and kill cancer cells. Obinituzaumab is an antibody that targets the lymphoma cells. The drugs are given intravenously .
Who can participate
Patients who:
- Have had the cancer return or not respond to at least two previous regimes of treatment, at least one including a drug such as Rituximab
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.